ADA 2018

In part 2 of this Exclusive Interview, Tracey Brown explains her varied stops along her road to becoming the CEO of the ADA in a conversation with Diabetes in Control Publisher Steve Freed.

In part 3 of this Exclusive Interview, Tracey Brown talks with Diabetes in Control Publisher Steve Freed about her vision for the ADA and the need to educate and increase awareness.

In part 4, the conclusion of this Exclusive Interview, Tracey Brown talks with Diabetes in Control Publisher Steve Freed about her disease management and reaching others to manage their diabetes as well.

Todd Hobbs, MD, is Vice President and Diabetes Chief Medical Officer for Novo Nordisk in North America, where he leads the organization’s focus on the implications of diabetes for the patient, healthcare system and healthcare professionals. As the Diabetes Chief Medical Officer for Novo Nordisk in North America, he focuses on the implications of diabetes for the company and for patients, for healthcare professionals and for healthcare systems. He provides medical guidance and input to the clinical development and life cycle management strategies for diabetes and obesity-related projects, as well as input into the R&D pipeline and participate in consultant advisory boards. Prior to joining the Novo Nordisk team in 2004, he attended the University of Louisville School of Medicine and then serviced as a resident at the Anderson Area Medical Center in South Carolina.

In this Exclusive Interview transcript, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of four major Novo Nordisk studies and their implications.

In this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of four major Novo Nordisk studies and their implications.

In part 1 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the results of their Pioneer One Study, the first to report on oral semaglutide, and what it means for people with type 1 and type 2.

In part 2 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the standings of the oral GLP-1 drug and their work on another oral drug.

In part 3 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the results of the SUSTAIN-7 trial and their implications for diabetes patients.

In part 4 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the benefits of both an SGLT-2 and GLP-1 injectable, as found in the Dual 9 study.